Non-Exudative Macular Degeneration and Management

  • Thomas R. Friberg
  • Kenneth T. Wals
Part of the Aging Medicine book series (AGME)


Non-exudative, age-related macular degeneration, which accounts for 85 percent of AMD cases, includes a spectrum of macular pathology. In its most mild form, the macula possesses few Drusen or retinal pigmentary epithelial (RPE) change with no visual disability. At the other end of this spectrum, the macula is affected by large areas of RPE atrophy, with devastating loss of central vision.

This chapter examines normal and pathologic changes in the macular leading to non-exudative macular degeneration, and reviews the clinical trials that have been performed on patients with this disease.


macular degeneration Drusen AREDS PTAMD CAPT CNVPT rheophoresis MIRA laser AMD 


  1. 1.
    National Advisory Eye Council (1993) Vision research: a national plan 1994–1998. NIH publication no. 93–3186. US Department of Health and Human Services, Bethesda, MDGoogle Scholar
  2. 2.
    Age-Related Eye Disease Study Research Group. (2003) Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Opthhalmol 121:1621–24CrossRefGoogle Scholar
  3. 3.
    Klein R, Klein BEK, Linton KLP (1992) Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmol 99:933–43Google Scholar
  4. 4.
    Bressler SB, Maguire MD, Bressler NB, Fine SL (1990) Relationship of Drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch Ophthalmol 108:1442–7PubMedGoogle Scholar
  5. 5.
    Age-Related Eye Disease Study Research Group. (2001) A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119(10):1417–36Google Scholar
  6. 6.
    Complications of Age-Related Macular Degeneration Prevention Trial Research Group. (2006) Laser treatment in patients with bilateral large Drusen. Ophthalmol 113:1974–86CrossRefGoogle Scholar
  7. 7.
    Friberg TR, Musch, DC, Lim JI, et al. (2006) PTAMD Study Group. Prophylactic treatment of age-related macular degeneration report number 1: 810–nanometer laser to eyes with Drusen. Unilaterally eligible patients. Ophthalmol 113:612–22CrossRefGoogle Scholar
  8. 8.
    Choroidal Neovascularization Prevention Trial Research Group. (1998) Laser treatment in eyes with large Drusen. Ophthalmol 105:11–23CrossRefGoogle Scholar
  9. 9.
    Pulido JS, Sanders K, Klingel R (2005) Rheophoresis for age-related macular degeneration: clinical results and putative mechanism of action. Can J Ophthalmol 40(3):332–40PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Thomas R. Friberg
    • 1
  • Kenneth T. Wals
    • 1
  1. 1.UPMC-Eye CentreUPMC-Eye CentreUniversity of PittsburghPittsburghPA

Personalised recommendations